查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128977

視網膜藥物市場：依藥物類別、劑型、性別、適應症、通路、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Retinal Drugs Market, By Drug Class, By Formulation, By Availability, By Indication, By Distribution Channel, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 305 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，視網膜藥物的市場規模將達到 242.13 億美元，並預計從 2026 年到 2033 年將以 8.1% 的複合年成長率成長。

視網膜療法是一系列用於治療影響眼後部各種視網膜疾病的藥物，包括但不限於老齡化黃斑部病變（AMD）、糖尿病視網膜病變（DR）和視網膜靜脈阻塞（RVO）。它們透過調節神經視網膜和脈絡膜的血管生成、發炎和基因表現發揮作用。視網膜療法包括功能性療法（抗VEGF生技藥品、皮質類固醇懸浮液或基因編輯因子）、最佳給藥途徑（溶液、植入、微粒或細胞遞送系統）以及利用藥物遞送動力學和影像引導系統的眼內給藥技術（玻璃體內注射）。這些療法透過實現標靶治療、持續藥物傳遞和改善視覺功能，從而改善視網膜疾病的治療效果。

視網膜藥物市場－市場動態

視網膜疾病發生率的上升正在推動市場成長。

視網膜疾病發生率的上升正在推動視網膜藥物市場的發展。這主要是由於糖尿病視網膜病變和老齡化黃斑部病變等疾病的盛行率不斷上升，使得人們迫切需要有效的治療方法，以在疾病早期階段預防視力喪失。例如，根據歐盟委員會的CORDIS報告，到2026年，將有多達4.2億人患有某種形式的視網膜疾病，而且由於老年人口比例的成長和糖尿病患者人數的增加，預計未來幾十年這一數字還將繼續成長。歐盟資助的「NeoVasculoStop」計畫表明，由於對某些活性物質的發現和研發，大約有25種化合物有可能透過光誘導與受體相互作用而發揮作用。其中，一些活性最強的物質即使在動物（大鼠和兔子）中以極低劑量也顯示出很高的療效。這些進展正在加速對用於治療視網膜疾病的尖端解決方案的需求。

視網膜藥物市場－市場區隔分析

全球視網膜藥物市場按藥物類別、劑型、可用性、適應症、分銷管道和地區細分。

就藥物類別而言，抗VEGF藥物在視網膜藥物市場佔有主要佔有率。這是因為抗VEGF藥物能夠抑制異常血管增生和滲漏，用於治療老齡化黃斑部病變、糖尿病黃斑部水腫和視網膜靜脈阻塞。 2026年4月，再生元公司獲得美國食品藥物管理局（FDA）批准，將其抗VEGF食品藥物管理局EYLEA HD®（阿柏西普）8毫克的給藥間隔延長至每20週一次，用於治療濕性老齡化黃斑部病變和糖尿病黃斑部水腫患者。這項進展有望透過提高用藥便利性來促進抗VEGF藥物的使用。

視網膜藥物市場—區域趨勢

由於視網膜疾病病例不斷增加、藥物研發進展以及監管支持，北美在全球視網膜藥物市場佔據著舉足輕重的地位。 2026年5月，美國食品藥物管理局（FDA）報告稱，其藥物評估與研究中心（CDER）審查了500多份應用人工智慧（AI）的藥物申請，這表明人工智慧已應用於美國藥物研發流程的各個階段：臨床前、臨床、上市後以及生產製造。此外，FDA已收到800多條關於其關於人工智慧在藥物研發中應用的討論文件的意見，並成立了人工智慧委員會來管理FDA內部的相關活動。同時，FDA和歐洲藥品管理局（EMA）制定了10項原則，旨在促進在藥品和生技藥品研發中負責任地使用人工智慧。這些進展透過創新、監管支援和人工智慧驅動的藥物研發，進一步鞏固了北美在該領域的地位。

目錄

第1章：視網膜藥物市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：視網膜藥物市場的主要趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：視網膜藥物產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：視網膜藥物市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：視網膜藥物市場趨勢

  • 視網膜藥物市場佔有率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 視網膜藥物市場：依藥物類別分類

  • 概述
    • 基於細分市場的市場佔有率分析：按藥物類別分類
    • 前列腺素
    • Rho激酶抑制劑
    • 抗組織胺藥
    • 抗 VEGF 藥物
    • NSAIDs
    • 其他

第8章 視網膜藥物市場：以劑型分類

  • 概述
    • 基於細分市場的市佔率分析：依配方分類
    • 軟膏
    • 膠囊和片劑
    • 眼藥水
    • 凝膠
    • 眼藥水及懸浮液

第9章 視網膜藥物市場：依性別分類的供應情況

  • 概述
    • 基於細分市場的市場佔有率分析：按性別分類的可用性
    • 處方藥
    • 非處方藥

第10章 視網膜藥物市場：依適應症分類

  • 概述
    • 基於細分市場的市佔率分析：按適應症
    • 感染疾病
    • 青光眼
    • 乾眼症
    • 糖尿病視網膜病變
    • 過敏
    • 其他

第11章 視網膜藥物市場：依分銷管道分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 網路藥房
    • 醫院藥房
    • 零售藥房

第12章 視網膜藥物市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第13章：主要供應商分析：視網膜藥物產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Bayer AG
    • Alcon Inc.
    • Alimera Sciences Inc.
    • Bausch+Lomb Corporation
    • MeiraGTx Holdings plc
    • Apellis Pharmaceuticals Inc.
    • Amgen Inc.
    • Santen Pharmaceutical Co. Ltd.
    • EyePoint Pharmaceuticals Inc.
    • Ocular Therapeutix Inc.
    • Clearside Biomedical Inc.
    • Adverum BIoTechnologies Inc.
    • Kodiak Sciences Inc.
    • Astellas Pharma Inc.
    • 其他

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7345

Retinal Drugs market size was valued at US$ 24,201.3 Million in 2025, expanding at a CAGR of 8.1% from 2026 to 2033.

Retinal drugs can be defined as a set of medicinal agents that aid in treating different retinal diseases that involve the back portion of the eye that may include but not be limited to age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO) via regulation of angiogenesis, inflammation, and gene expression of the neural retina and choroid. Retinal drugs consist of a functional therapy agent (biologics for VEGF, suspensions of corticosteroids, or gene editing factors), an optimal delivery method (solutions, implants, microparticles, or cell delivery systems), and an intraocular administration technique (intravitreal injection) that makes use of the drug delivery kinetics and imaging guidance system. These therapies improve retinal disease management by enabling targeted treatment, sustained drug delivery, and better visual outcomes.

Retinal Drugs Market- Market Dynamics

Rising Prevalence of Retinal Disorders to Support Market Growth

The rising prevalence of retinal disorders is fuelling the Retinal Drugs market due to the increasing prevalence of conditions such as diabetic retinopathy and age-related macular degeneration, requiring effective treatments to avoid losing vision in the early stages of the development of the disease. For instance, in 2026, according to the European Commission's CORDIS, as many as 420 million individuals were already suffering from one of the diseases of the retina by 2026, and this figure is expected to grow further in coming decades owing to an increased ratio of elderly individuals as well as those suffering from diabetes. According to the NeoVasculoStop project funded by the EU, the discovery and research into a class of active substances showed that some 25 compounds were found to have the potential to exert their action via a photo-induced interaction with the receptor, with the most potent substance being highly efficient even at extremely low doses in animals (rats and rabbits). These developments are speeding up the demand for new-edge solutions for the treatment of retinal disorders.

Retinal Drugs Market- Segmentation Analysis:

The Global Retinal Drugs market is segmented on the basis of Drug Class, Formulation, Availability, Indication, Distribution Channel, and Region.

By drug class, anti-VEGF agents hold a major share in the Retinal Drugs market because of the involvement of anti-VEGF medicines in the treatment of abnormal growth of blood vessels and their leakage in the treatment of age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion. In April 2026, Regeneron obtained the FDA approval to extend the dosing interval of EYLEA HD(R) (aflibercept) 8 mg, an anti-VEGF medication, to every 20 weeks for patients with wet age-related macular degeneration and diabetic macular oedema. This development is anticipated to boost the usage of anti-VEGF medications through convenience.

Retinal Drugs Market- Geographical Insights

North America holds a prominent position in the global Retinal Drugs market because of the increase in cases of retinal diseases, improvement in drug development, and regulatory support. In May 2026, as reported by the U.S. Food and Drug Administration (Gov), the Center for Drug Evaluation and Research (CDER) has reviewed more than 500 drug applications that involve AI, indicating the application of AI in nonclinical, clinical, post-market, and manufacturing phases in the process of drug development in the US. Further, the US FDA had received more than 800 comments from the public on the discussion paper issued by the agency on the use of AI in drug development and also had set up the AI Council for managing such activities within the agency. Moreover, the US FDA and EMA have come up with 10 principles to encourage responsible use of AI in drug and biologics development. These advancements strengthen North America's position through innovation, regulatory support, and AI-driven drug development.

Retinal Drugs Market- Competitive Landscape:

The Retinal Drugs market features a competitive landscape characterized by therapeutic innovation, a growing number of treatment alternatives, and increasing demand for effective retinal disease management. Key competitors are AbbVie Inc., Bayer AG, Alcon Inc., Alimera Sciences Inc., and Bausch Health Co. Inc. In January 2025, AbbVie and REGENXBIO will continue their cooperation concerning ABBV-RGX-314 for the treatment of retinal diseases and the development of the Phase 3 trial of this treatment in the case of diabetic retinopathy, as well as the continuation of pivotal trials in wet age-related macular degeneration in an attempt to make potential one-time therapies for retinal diseases available to patients. The companies have plans to conduct Phase 3 trials of this treatment in the case of diabetic retinopathy and continue pivotal trials in the case of wet age-related macular degeneration. These strategic advancements are expected to intensify competition and accelerate innovation in retinal disease treatments.

Recent Developments:

In January 2026, Bayer was granted marketing authorization by the European Commission for Eylea 8 mg (aflibercept) in macular edema due to retinal vein occlusion, marking the third indication of the drug and allowing extended intervals between doses for patients.

In September 2025, Alcon entered into an agreement to acquire LumiThera Inc., which has developed a light therapy, Valeda, for early and intermediate stages of dry age-related macular degeneration. This marked the expansion of the retinal health product line of Alcon into light therapies for dry AMD.

In January 2025, Bausch + Lomb acquired Whitecap Biosciences with its pipeline of investigational agents for glaucoma and geographic atrophy, which is now its focus on retinal diseases related to vision impairment.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINAL DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Bayer AG
  • Alcon Inc.
  • Alimera Sciences Inc.
  • Bausch + Lomb Corporation
  • MeiraGTx Holdings plc
  • Apellis Pharmaceuticals Inc.
  • Amgen Inc.
  • Santen Pharmaceutical Co. Ltd.
  • EyePoint Pharmaceuticals Inc.
  • Ocular Therapeutix Inc.
  • Clearside Biomedical Inc.
  • Adverum Biotechnologies Inc.
  • Kodiak Sciences Inc.
  • Astellas Pharma Inc.
  • Others

GLOBAL RETINAL DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

  • Prostaglandins
  • Rho kinase inhibitor
  • Antihistamine
  • Anti-VEGF Agents
  • NSAIDs
  • Others

GLOBAL RETINAL DRUGS MARKET, BY FORMULATION- MARKET ANALYSIS, 2020 - 2033

  • Ointments
  • Capsules & Tablets
  • Eye Drops
  • Gels
  • Eye Solutions & Suspensions

GLOBAL RETINAL DRUGS MARKET, BY AVAILABILITY- MARKET ANALYSIS, 2020 - 2033

  • Prescription Drugs
  • OTC

GLOBAL RETINAL DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033

  • Infection
  • Glaucoma
  • Dry Eye
  • Diabetic
  • Retinopathy
  • Allergies
  • Others

GLOBAL RETINAL DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

GLOBAL RETINAL DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Retinal Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Retinal Drugs Market Snippet by Drug Class
    • 2.1.2. Retinal Drugs Market Snippet by Formulation
    • 2.1.3. Retinal Drugs Market Snippet by Availability
    • 2.1.4. Retinal Drugs Market Snippet by Indication
    • 2.1.5. Retinal Drugs Market Snippet by Distribution Channel
    • 2.1.6. Retinal Drugs Market Snippet by Country
    • 2.1.7. Retinal Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Retinal Drugs Key Market Trends

  • 3.1. Retinal Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Retinal Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Retinal Drugs Market Opportunities
  • 3.4. Retinal Drugs Market Future Trends

4. Retinal Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Retinal Drugs Market : Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Retinal Drugs Market Landscape

  • 6.1. Retinal Drugs Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Retinal Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
    • 7.1.2. Prostaglandins
    • 7.1.3. Rho kinase inhibitor
    • 7.1.4. Antihistamine
    • 7.1.5. Anti-VEGF Agents
    • 7.1.6. NSAIDs
    • 7.1.7. Others

8. Retinal Drugs Market - By Formulation

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Formulation, 2025 & 2033 (%)
    • 8.1.2. Ointments
    • 8.1.3. Capsules & Tablets
    • 8.1.4. Eye Drops
    • 8.1.5. Gels
    • 8.1.6. Eye Solutions & Suspensions

9. Retinal Drugs Market - By Availability

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Availability, 2025 & 2033 (%)
    • 9.1.2. Prescription Drugs
    • 9.1.3. OTC

10. Retinal Drugs Market - By Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
    • 10.1.2. Infection
    • 10.1.3. Glaucoma
    • 10.1.4. Dry Eye
    • 10.1.5. Diabetic
    • 10.1.6. Retinopathy
    • 10.1.7. Allergies
    • 10.1.8. Others

11. Retinal Drugs Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
    • 11.1.2. Online Pharmacies
    • 11.1.3. Hospital Pharmacies
    • 11.1.4. Retail Pharmacies

12. Retinal Drugs Market - By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Retinal Drugs Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Retinal Drugs Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.18. Denmark
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.18.3. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.18.4. Denmark Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.18.5. Denmark Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.18.6. Denmark Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.18.7. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.3.19. Rest of Europe
      • 12.3.19.1. Overview
      • 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.19.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.3.19.4. Rest of the Europe Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.3.19.5. Rest of the Europe Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.3.19.6. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.3.19.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Retinal Drugs Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.17. Taiwan
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.17.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.17.4. Taiwan Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.17.5. Taiwan Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.17.6. Taiwan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.17.7. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.18. Vietnam
      • 12.4.18.1. Overview
      • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.18.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.18.4. Vietnam Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.18.5. Vietnam Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.18.6. Vietnam Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.18.7. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.4.19. Rest of APAC
      • 12.4.19.1. Overview
      • 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.19.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.4.19.4. Rest of APAC Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.4.19.5. Rest of APAC Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.4.19.6. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.4.19.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Retinal Drugs Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Retinal Drugs Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.15. Iran
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.15.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.15.4. Iran Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.15.5. Iran Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.15.6. Iran Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.15.7. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.16. Qatar
      • 12.6.16.1. Overview
      • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.16.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.16.4. Qatar Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.16.5. Qatar Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.16.6. Qatar Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.16.7. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 12.6.17. Rest of MEA
      • 12.6.17.1. Overview
      • 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.17.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 12.6.17.4. Rest of MEA Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
      • 12.6.17.5. Rest of MEA Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
      • 12.6.17.6. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 12.6.17.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Retinal Drugs Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. AbbVie Inc.
    • 13.2.2. F. Hoffmann-La Roche Ltd.
    • 13.2.3. Novartis AG
    • 13.2.4. Regeneron Pharmaceuticals Inc.
    • 13.2.5. Bayer AG
    • 13.2.6. Alcon Inc.
    • 13.2.7. Alimera Sciences Inc.
    • 13.2.8. Bausch + Lomb Corporation
    • 13.2.9. MeiraGTx Holdings plc
    • 13.2.10. Apellis Pharmaceuticals Inc.
    • 13.2.11. Amgen Inc.
    • 13.2.12. Santen Pharmaceutical Co. Ltd.
    • 13.2.13. EyePoint Pharmaceuticals Inc.
    • 13.2.14. Ocular Therapeutix Inc.
    • 13.2.15. Clearside Biomedical Inc.
    • 13.2.16. Adverum Biotechnologies Inc.
    • 13.2.17. Kodiak Sciences Inc.
    • 13.2.18. Astellas Pharma Inc.
    • 13.2.19. Others

14. 360 Degree AnalystView

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us